Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Paroxetine 12.5 milligrams tablet
Paroxetine 12.5 milligrams · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment sequence A/B/C | EXPERIMENTAL | Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Treatment sequence A/C/B | EXPERIMENTAL | Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Treatment sequence B/A/C | EXPERIMENTAL | Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Treatment sequence B/C/A | EXPERIMENTAL | Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Treatment sequence C/A/B | EXPERIMENTAL | Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Treatment sequence C/B/A | EXPERIMENTAL | Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period. |
| Name | Type | Description |
|---|---|---|
| Paroxetine 12.5 milligrams tablet | DRUG | Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally. |
| Paroxetine 25 milligrams tablet | DRUG | Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally. |
| Paroxetine 50 milligrams tablet | DRUG | Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally. |
Inclusion Criteria: * Healthy Japanese adult males between 20 and 64 years of age inclusive * BMI 18.50 or higher and \< 25.00 kg/m2, and bodyweight 50 kg or higher * Non-smokers * AST, ALT, ALP, gamma-GTP and total-bilirubin are below the upper limit of normal range * QTc(B) interval \<450 msec * ...
Top 20 of 29 competitors